TPCW
RNA

TD Private Client Wealth’s Atrium Therapeutics RNA Stock Holding History

TD Private Client Wealth’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$995 Buy
+74
New +$967 ﹤0.01% 1473

Other funds holding RNA

SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CL
CRCM LP San Francisco, California $152M AUM 26.3% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

TD Private Client Wealth's RNA Position: Q2 2026 in Review

TD Private Client Wealth opened a new position in Atrium Therapeutics (RNA) in Q2 2026: 74 shares worth $995. The stake represents ﹤0.01% of the portfolio and ranks #1473 among its holdings.

155 funds tracked by Wall St. Rank hold RNA as of Q2 2026.

  • TD Private Client Wealth held 74 shares of Atrium Therapeutics worth $995 as of Q2 2026.
  • Atrium Therapeutics was a new TD Private Client Wealth position in Q2 2026.
  • Atrium Therapeutics made up ﹤0.01% of TD Private Client Wealth's portfolio in Q2 2026, its #1473 holding.
  • 155 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q2 2026.

Based on TD Private Client Wealth's 13F filing for Q2 2026, filed 4 Aug 2026.